Navigation Links
Takeda San Francisco, Inc. Appoints Michael Buckley, Ph.D. Vice President of Process Sciences
Date:10/12/2009

SAN FRANCISCO, Oct. 12 /PRNewswire/ -- Takeda San Francisco, Inc. announced today that Michael Buckley, Ph.D., has joined the company as vice president of process sciences. Dr. Buckley will be responsible for directing all aspects of the materials supply to support research and prepare for production of therapeutic antibody candidates at Takeda's antibody IND engine and center of excellence for biologics.

"Mike brings over 20 years of experience in the biopharmaceutical industry and is a great addition to the Takeda San Francisco management team," said Mary Haak-Frendscho, Ph.D., president and chief scientific officer, Takeda San Francisco. "Mike's extensive experience covers all key aspects of antibody drug production, purification, formulation and analytical development. He will play an important role as we expand Takeda's biologics R&D capabilities in order to realize our goals of discovering and advancing superior therapeutics to contribute to the health of individuals."

Dr. Buckley previously has held executive positions with Neugenesis Corporation, Genitope Corporation and Corixa Corporation, leading multi-disciplinary groups in process development, manufacturing and materials management. He also has written multiple IND, BLA and drug master file sections for regulatory submissions. While at Corixa, Dr. Buckley was instrumental in the development of the first centrally manufactured radiopharmaceutical-Iodine-131 antibody (Bexxar(TM)). He holds a Ph.D. in immunology from the UMDNJ Graduate School of Biomedical Sciences, Newark, NJ.

About Takeda San Francisco, Inc.

Takeda San Francisco, Inc. (TSF), established in November 2007 as a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Osaka, Japan, is Takeda's Biologics Center of Excellence and Antibody IND Engine for human antibody therapeutics for the treatment of cancer, inflammation and metabolic diseases. TSF supports Takeda's therapeutic antibody initiative in close collaboration with Takeda's other R&D organizations. Additional information about Takeda San Francisco is available at http://www.takedasf.com.

About Takeda Pharmaceutical Company Limited

Founded in 1781 and located in Osaka, Japan, Takeda (TSE: 4502) is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. Additional information about Takeda is available through its corporate website, http://www.takeda.com.

SOURCE Takeda San Francisco, Inc.


'/>"/>
SOURCE Takeda San Francisco, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Takeda to Establish Four Sales and Marketing Subsidiaries to Expand Its Operations in Mexico, Turkey and Five Other Countries in Europe
2. Takeda Receives FDA Complete Response Letter for the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
3. Takeda Initiates Cardiovascular Outcomes Trial for Alogliptin, An Investigational Treatment for Type 2 Diabetes
4. Takeda Provides Update on the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl)
5. Takeda Receives FDA Complete Response Letter for Alogliptin, an Investigational Treatment for Type 2 Diabetes
6. Takeda to Revise Timing of Alogliptin and Alogliptin/ACTOS MAA Filings in Europe
7. Takeda Initiates Two Phase III Studies with Vedolizumab (MLN0002) in Patients with Inflammatory Bowel Disease
8. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
9. Takedas Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed
10. Takeda Submits a New Drug Application in the U.S. for Alogliptin (SYR-322) / ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
11. Takeda Doses First Patient in a U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... -- New research provides evidence that an old drug may provide ... released today that will be presented at the American ... Boston , April 22 to 28, 2017. ... the oral drug levodopa has long been considered the gold ... disease progresses, the effects of the medication can partially wear ...
(Date:4/19/2017)... April 19, 2017  SARES•REGIS Group leased the ... developing at Conejo Spectrum Business Park in ... Atara Biotherapeutics, Inc. , a biopharmaceutical company developing ... diseases that have been underserved by scientific innovation, ... for cancer, autoimmune and infectious disease. ...
(Date:4/18/2017)... -- Cogentix Medical, Inc. (NASDAQ: CGNT), a global medical ... Gynecology markets with innovative and proprietary products, will release ... 2017 after the market close on Tuesday, May 2, ... conference call and webcast to discuss its financial results ... 4:30 p.m. Eastern Time (3:30 p.m. Central Time). ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... ... Saad B. Chaudhary, MD is committed to providing the highest quality of spine care to ... preventative care with all my patients to alleviate possible future issues. I am pleased to ... my office and my trained staff will assist you in any way possible.” , Dr. ...
(Date:4/25/2017)... ... April 25, 2017 , ... Vetoquinol ... is introducing Flexadin UCII, part of the EQUISTRO line, at this week’s Rolex ... in horses at the immunologic level. , The scientifically-developed Flexadin UCII supports the ...
(Date:4/24/2017)... ... ... Michael Vick announced his retirement earlier this year from the NFL after thirteen ... in the 2001 NFL Draft, to the Atlanta Falcons, made four Pro Bowl appearances ... yards by a quarterback (6,109) and the most rushing yards by a quarterback in ...
(Date:4/24/2017)... ... April 24, 2017 , ... NEPC Director Kevin Welner has ... Research Award. The award honors scholars exemplary in their capacity to communicate important ... has demonstrated the capacity to deepen the public’s understanding and appreciation of the ...
(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... Sean Fay ... Oxiclean, Space Bag, Sonicare Toothbrush, Juiceman Juicer, and the George Foreman Grill (which sold ... any other marketer in the last 25 years. , Now, due to changes in ...
Breaking Medicine News(10 mins):